Navigation Links
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
Date:10/24/2007

which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer in the fourth quarter of 2007, evaluating RDEA119 for inflammatory diseases next year, and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Blurb shows that print still captures imaginations
2. Kauffman study shows consistent entrepreneurial growth
3. Directory shows high-tech growth spurt in Dane Co.
4. Stem cell therapy shows visionary promise
5. TDS restates years of revenues, shows slight profit drop
6. As BIO shows mass of competition, hunt for partners is on
7. UW shows why avian flu hasnt spread among humans yet
8. NameProtect study shows 92% of top brands losing out on search engines
9. Stem cell breakthrough by UW shows why federal research should be broadened
10. Student survey shows surging demand for wireless access
11. Wisconsins tech employment shows increase, HR firm reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA theory ... of these latent viruses is the Epstein Barr Virus (EBV), ... arthritis (RA) is a chronic inflammatory disease that destroys the ... that RA patients have high concentrations of EBV DNA in ...
(Date:1/15/2014)... January 15, 2014 Freeslate, Inc ... today announced that Lupin Limited, one of India’s top ... CM Protégé PharmD System for high throughput solid ... is focused on a wide range of quality, affordable ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that ... investment conferences. , Vincent Milano, president and chief ... 20th Annual Healthcare Conference at 4:30 P.M. EST on ... held at the Waldorf=Astoria in New York City. , ...
... 50/50 joint venture agreement signed with Hunan, Biopharmaceutical ... manufacturing facility, - Biologics: 23% growth in sales and to ... of KINLYTIC(TM) thrombolytic, agent for pulmonary embolism, ... under, agreement, - Dr. Mark ...
... DNDN ) today announced that management will present at the following upcoming ... New York City, Tuesday, November 10, 2009, ... Phoenix, Arizona, Friday, November 13, 2009, ... Conference, New York City, Tuesday, November 17, ...
Cached Biology Technology:ViroPharma to Present at Three November Healthcare Conferences 2Microbix Biosystems Provides a Corporate Update 2Microbix Biosystems Provides a Corporate Update 3Microbix Biosystems Provides a Corporate Update 4Microbix Biosystems Provides a Corporate Update 5Microbix Biosystems Provides a Corporate Update 6Microbix Biosystems Provides a Corporate Update 7
(Date:4/20/2014)... analysis growing in importance for both basic researchers ... and the University of Maryland have developed a ... of gene activity from RNA sequencing (RNA-seq) data., ... famously speedy fish, estimates of gene expression that ... a few minutes, with accuracy that equals or ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
(Date:4/18/2014)... techniques like X-ray crystallography and nuclear magnetic resonance imaging ... of molecules, but such efforts have long been hampered ... a specific molecule and often in ordered and crystalized ... impossible to peer into the structure of most molecules. ... be a thing of the past. , A ...
Breaking Biology News(10 mins):Computational method dramatically speeds up estimates of gene expression 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3MRI, on a molecular scale 2MRI, on a molecular scale 3
... voices, but now helium is also helping people with ... the University of Alberta in Edmonton, Canada have discovered ... allowed patients with chronic obstructive pulmonary disease (COPD) to ... per cent. COPD is a disease of the lungs ...
... For the first time in humans, scientists have found ... injuries caused by repetitive motion. , Their findings ... debilitating conditions such as carpal tunnel syndrome and tendonitis. ... researchers Ann Barr and Mary Barbe and their doctoral ...
... Two researchers from the University Hospital and the Center ... Navarra have published an article in Nature Cancer ... the area of cancer studies. The article, written by ... from the United States and Great Britain, addresses the ...
Cached Biology News:Helium helps patients breathe easier 2Red flag for repetitive stress injuries identified for first time in humans 2Researchers from the University of Navarra analyze new kinds of cancer-fighting antibodies 2